Objective-Serum Dkk-1 (dickkopf-1) level has been shown to be elevated in patients with ischemic stroke, but its impact on clinical outcomes of ischemic stroke remains unclear. The aim of this study is to investigate the association between serum Dkk-1 and prognosis of ischemic stroke. Approach and Results-We measured serum Dkk-1 levels in 3178 patients with ischemic stroke from CATIS (China Antihypertensive Trial in Acute Ischemic Stroke). The primary outcome was a combination of all-cause mortality and major disability (modified Rankin scale score, ≥3) at 1 year after stroke. Secondary outcomes were stroke recurrence and vascular events. After multivariate adjustment, elevated Dkk-1 levels were associated with an increased risk of primary outcome (odds ratio, 1.40; 95% CI, 1.03-1.89; P trend =0.015) when 2 extreme quartiles were compared. Each SD increase of log-transformed Dkk-1 was associated with 12% (95% CI, 1%-24%) increased risk of primary outcome. Multiple-adjusted spline regression model showed a linear association between serum Dkk-1 and risk of primary outcome (P for linearity, 0.039). Subgroup analyses further confirmed these associations. The addition of serum Dkk-1 to conventional risk factors improved the predictive power for primary outcome (net reclassification improvement: 10.11%, P=0.029; integrated discrimination improvement: 0.21%, P=0.028). Conclusions-High serum Dkk-1 levels at baseline were associated with poor prognosis at 1 year after ischemic stroke, suggesting that serum Dkk-1 may be a potential prognostic biomarker for ischemic stroke. Further studies from other samples of patients with ischemic stroke are needed to replicate our findings and to clarify the potential mechanisms. Visual Overview-An online visual overview is available for this article.
D
kk-1 (dickkopf-1)-the most widely studied secreted protein of Dickkopf family-is the best characterized and potent antagonist of Wnt canonical signaling pathway. 1 Dkk-1 has been established as a novel mediator in endothelial cell injury, and it can promote release of inflammatory cytokines. 2 Recently, increased Dkk-1 expression was found in murine atherosclerotic lesions and human carotid plaques, 2 indicating that Dkk-1 is involved in the atherosclerosis process. Consistently, high serum Dkk-1 level was reported in patients with ischemic stroke, 3 stable angina, 2 and myocardial infarction. 4, 5 Moreover, Dkk-1 was an independent predictor for long-term poor prognosis of acute coronary syndrome 6 and symptomatic aortic stenosis. 7 Data from animal studies showed that induction of Dkk-1 contributed to the development of ischemic neuronal death, 8, 9 and blocking Dkk-1 could protect neurons against ischemic damage 8 and decreased infarction volume after focal brain ischemia. 9 All these evidence suggested that serum Dkk-1 might be a prognostic biomarker for ischemic stroke. To date, there were only 2 clinical studies examining the association of Dkk-1 with ischemic stroke prognosis, and they found no significant association between them. 3, 10 However, both studies are underpowered because of small sample sizes (<100) and short follow-up time (3 months). 3, 10 Therefore, the effect of serum Dkk-1 on the clinical outcomes of ischemic stroke remains unclear.
Established traditional risk factors, such as older age, hypertension, and diabetes mellitus, can only explain part of poor prognosis of ischemic stroke, 11, 12 so that novel biomarkers to identify patients at high risk of poor prognosis will assist the selection of patients for aggressive monitoring and therapeutic interventions. Well-designed prospective studies with sufficient statistical power on the potential association between serum Dkk-1 levels and clinical outcomes of ischemic stroke are needed. The aim of this study is to prospectively investigate the association between serum Dkk-1 and prognosis of ischemic stroke among patients from the CATIS (China Antihypertensive Trial in Acute Ischemic Stroke).
Materials and Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
Study Participants
This study was drawn from the CATIS-a multicenter, single-blind, blinded end points, randomized clinical trial conducted in 26 hospitals across China from August 2009 to May 2014. Details on the study design, data collection, and major results of the CATIS have been reported previously. 13 Briefly, a total of 4071 patients were recruited in the CATIS. The inclusion criteria of CATIS were to meet all of the following: (1) age ≥22 years, (2) having ischemic stroke confirmed by computed tomography or magnetic resonance imaging of the brain within 48 hours of symptom onset, and (3) having an elevated systolic blood pressure (BP) between 140 and <220 mm Hg. The exclusion criteria of CATIS were to meet one of the following: (1) having a systolic BP ≥220 or diastolic BP ≥120 mm Hg, (2) having severe heart failure, (3) having acute myocardial infarction or unstable angina, (4) having atrial fibrillation, (5) having aortic dissection, (6) having cerebrovascular stenosis (≥70%), (7) having resistant hypertension, (8) being in a deep coma, or (9) having been treated with intravenous thrombolytic therapy. For the present study, a further 893 patients were excluded because we did not have their blood samples, or some collected samples were hemolyzed during blood sample collection or serum separation process. Finally, a total of 3178 patients were included in this study.
The CATIS trial is registered (URL: http://www.clinicaltrials. gov; unique identifier: NCT01840072). The protocol and data collection of the CATIS trial was approved by the Institutional Review Boards or Ethical Committees at Soochow University in China, Tulane University in the United States, and all participating hospitals. Written consent was obtained from all study participants or their immediate family members.
Data Collection
Baseline data on demographic characteristics, medical history, and clinical features were collected at the time of enrollment. Stroke severity was assessed using the National Institutes of Health Stroke Scale (NIHSS) by trained neurologists at baseline.
14 Ischemic stroke was classified as large artery atherosclerosis (thrombotic), cardiac embolism (embolic), and small artery occlusion lacunae (lacunar) according to the symptoms and imaging data of the patients. 15 Three BP measurements were obtained at baseline by trained nurses while the patient was in the supine position using a standard mercury sphygmomanometer. The mean of the 3 BP records was used in analyses. Routine laboratory determinations (blood glucose, blood lipids, blood creatinine, etc) were performed for all enrolled patients in each participating hospital at admission.
Serum Dkk-1 Measurement
Fasting blood samples were collected after at least 8 hours of fasting within 24 hours of hospital admission. All serum samples were separated at clinical laboratories of the participating hospitals and immediately frozen at −80°C until laboratory testing. Serum Dkk-1 levels were measured centrally in the Central Laboratory of School of Public Health in Soochow University with a commercially available ELISA kit (Catalog: DKK100B; R&D Systems, Inc, Minneapolis). A standard curve was constructed from which Dkk-1 concentrations of unknown samples were determined. The minimum detectable dose of Dkk-1 was 0.419 pg/mL, and all patients' serum Dkk-1 levels were much higher than the detection limit in the present study. Intra-assay and interassay coefficients of variation were <2.4% and 8.2%, respectively. Laboratory technicians who measured serum Dkk-1 were blind to the clinical characteristics and outcomes of the study participants.
Outcome Assessment
Participants were followed up in person at 1 year after acute ischemic stroke by trained neurologists who were unaware of treatment assignment. The primary outcome was a combination of all-cause mortality and major disability (modified Rankin scale score, 3-6). Secondary outcomes were stroke recurrence and vascular events (ie, vascular deaths, recurrent nonfatal stroke, nonfatal myocardial infarction, hospitalized and treated angina, hospitalized and treated congestive heart failure, and hospitalized and treated peripheral arterial disease). Death certificates were obtained for deceased patients, and hospital data were abstracted for stroke recurrence and vascular events. A trial-wide outcomes assessment committee, blinded to treatment assignment, reviewed and adjudicated vascular events based on the criteria established in ALLHAT (Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial).
Statistical Analysis
Baseline characteristics of study participants were presented according to the quartiles of baseline serum Dkk-1 levels, as well as in participants with and without primary outcome at 1 year follow-up. Tests for linear trend of baseline characteristics across Dkk-1 quartiles were performed using covariance analysis for continuous variables and χ 2 trend analysis for categorical variables. Baseline characteristics between patients with and without primary outcome were compared using a Student t test, Wilcoxon rank-sum test, or the χ 2 test as appropriate. Multivariate logistic regression and Cox proportional hazards models were used to assess the association between serum Dkk-1 and clinical outcomes when appropriate. Odds ratio, hazard ratio, and 95% CI were calculated for higher quartiles of Dkk-1 compared with the lowest quartile. Cardiovascular risk factors and prognostic factors were selected as potential covariates for clinical outcomes of ischemic stroke based on prior knowledge. The covariates included in the multivariable model were age, sex, time from onset to hospitalization, current smoking, alcohol consumption, dyslipidemia, blood glucose, systolic BP, log-transformed platelet counts, creatinine, high-sensitivity C-reactive protein, white blood In the secondary analyses, a receiver operating characteristic curve was configured to establish cutoff points of serum Dkk-1 levels that optimally predicted prognosis of acute ischemic stroke. We conducted subgroup analyses to assess the robustness of association between high serum Dkk-1 and prognosis of acute ischemic stroke. Interactions between serum Dkk-1 and subgroup variables on the clinical outcomes were tested in the models with interaction terms by the likelihood ratio test, adjusting for the aforementioned covariates unless the variable was used as a subgroup variable. Net reclassification improvement (NRI) and integrated discrimination improvement (IDI) were 2 indexes to assess improvement in model performance accomplished by adding new markers. 17 All conventional risk factors (aforementioned potential covariates) were directly incorporated into the model when To assess the improvement in risk prediction for poor prognosis of ischemic stroke by adding Dkk-1 to conventional risk factors, we calculated NRI and IDI through comparing these 2 models. Twotailed P <0.05 was considered to be statistically significant. All analyses were performed using SAS statistical software (version 9.4; Cary, NC).
Results

Baseline Characteristics
All baseline characteristics were balanced between patients who were assayed for serum Dkk-1 and all CATIS patients (Table I in the online-only Data Supplement), indicating that those assayed basically represent the total participants of CATIS. A total of 3178 patients (2029 men and 1149 women) were included in the current study, and the average age was 62 †The age-and sex-adjusted P value for the difference of baseline serum Dkk-1 between these 2 groups is 0.025. ‡Eight patients with both thrombotic and embolic subtypes, 68 patients with thrombotic and lacunar subtypes, 5 patients with embolic and lacunar subtypes, and 1 patient with all 3 subtypes.
years. The median serum Dkk-1 concentration was 4035.61 pg/mL (interquartile range, 3160.08-5149.18 pg/mL). The participants with higher serum Dkk-1 tended to be younger and had higher low-density lipoprotein cholesterol, platelet counts, white blood cell counts, and prevalence of embolic than those with lower serum Dkk-1 (Table 1) .
After 1 year of follow-up, 58 participants (1.83%) were lost to follow-up. Among the remaining participants, a total of 687 participants (22.02%) experienced primary outcome (Table 2) . Compared with participants who did not develop primary outcome, those who developed primary outcome were more likely to be older, women, and had higher systolic BP, low-density lipoprotein cholesterol, blood glucose, high-sensitivity C-reactive protein, white blood cell counts, baseline NIHSS score, and prevalence of history of coronary heart disease, history of diabetes mellitus and embolic stroke, and had shorter time from onset to randomization, lower triglyceride level, and lower prevalence of cigarette smoking, alcohol drinking, and family history of stroke. After age and sex adjustment, patients who developed primary outcome had higher serum Dkk-1 levels than those who did not develop primary outcome (P=0.025).
Association Between Serum Dkk-1 and Prognosis of Ischemic Stroke
The cumulative rates of primary outcome within 1 year among patients with ischemic stroke in 4 quartiles of serum Dkk-1 (from low to high) were 20.49%, 21.64%, 22.19%, and 23.75%, respectively (Table 3) . Compared with patients in the lowest quartile of Dkk-1, the odds ratios (95% CIs) of primary outcome, stroke recurrence, and vascular events for those in the highest quartile of Dkk-1 were 1.40 (1.03-1.89), 1.35 (0.83-2.20), and 1.14 (0.73-1.79), respectively, after adjustment for potential confounders, including baseline log-transformed platelet counts and high-sensitivity C-reactive protein, as well as white blood cell counts (model 2). Moreover, the risk of primary outcome reached statistical significance, and there was a trend that the risk increased with quartiles of Dkk-1 (P for trend, 0.015). Similarly, on continuous analyses, each SD increase of log-transformed Dkk-1 was associated with 12% (95% CI, 1%-24%) increased risk of primary Model 1, adjusted for age, sex, time from onset to hospitalization, current smoking, alcohol consumption, dyslipidemia, blood glucose, systolic BP, logtransformed platelet counts, creatinine, high-sensitivity C-reactive protein, white blood cell counts, and NIHSS score at baseline, history of hypertension, history of coronary heart disease, history of diabetes mellitus, family history of stroke, and ischemic stroke subtypes. Model 2, adjusted for model 1 and further adjusted for receiving immediate BP reduction. BP indicates blood pressure; Dkk-1, dickkopf-1; and NIHSS, National Institutes of Health stroke scale.
*Logistic regression models were applied because of the noneventive nature of major disability. †Cox proportional hazard models were performed. Association of serum Dkk-1 (dickkopf-1) with the risk of primary outcome (all-cause mortality or major disability) among patients with acute ischemic stroke. Odds ratios (ORs) and 95% CIs derived from restricted cubic spline regression, with knots placed at the 5th, 35th, 65th, and 95th percentiles of the distribution of serum Dkk-1. Reference point is the lowest quartile of serum Dkk-1 (3160.08 pg/mL). ORs were adjusted for the same variables as model 2 in Table 3 .
outcome (Table 3 ). In addition, multivariable-adjusted spline regression models showed a linear dose-response association between serum Dkk-1 and primary outcome (P for nonlinearity, 0.224; P for linearity, 0.039; Figure 1 ). However, there was no significant association of serum Dkk-1 with stroke recurrence or vascular events within 1 year after ischemic stroke in all patients or in those with different stroke pathogeneses ( Table 3; Table II online-only Data Supplement).
Subgroup Analyses on the Association Between Serum Dkk-1 and Prognosis of Ischemic Stroke
An optimal Dkk-1 cut point level (3814.88 pg/mL) was obtained from the receiver operating characteristic curve, and high serum Dkk-1 levels were associated with the primary outcome (odds ratio, 1.41; 95% CI, 1.14-1.75; P=0.002; Figure 2 ) after adjustment for potential confounders. In subgroup analyses stratified by age, sex, baseline systolic BP, history of hypertension, dyslipidemia, baseline NIHSS score, high-sensitivity C-reactive protein, white blood cell counts, platelet counts, cigarette smoking, alcohol consumption, and receiving immediate BP reduction medication, the modest positive associations between high Dkk-1 and primary outcome were observed in all subgroups and reached significant levels in most subgroups. No significant interaction between serum Dkk-1 levels and these interested factors on primary outcome was observed (all P for interaction, >0.05).
Incremental Prognostic Value of Serum Dkk-1 in Patients With Ischemic Stroke
We examined whether adding serum Dkk-1 to the conventional risk factors improved the risk prediction of clinical outcomes after acute ischemic stroke. As shown in Table 4 Subgroup analyses of the association between high serum Dkk-1 (dickkopf-1) and primary outcome (all-cause mortality or major disability). High serum Dkk-1 was defined as ≥3814.88 pg/mL (optimal cut point obtained from the receiver operating characteristic curve). In the multivariate models, confounding factors, such as age, sex, time from onset to hospitalization, current smoking, alcohol consumption, dyslipidemia, blood glucose, systolic blood pressure, log-transformed platelet counts, creatinine, high-sensitivity C-reactive protein, white blood cell counts, and National Institutes of Health stroke scale (NIHSS) score at baseline, history of hypertension, history of coronary heart disease, history of diabetes mellitus, family history of stroke, ischemic stroke subtypes, and receiving immediate blood pressure reduction were included unless the variable was used as a subgroup variable. OR indicates odds ratio.
Discussion
In this large-sample multicenter study based on CATIS, we examine the prospective association between serum Dkk-1 level and prognosis of ischemic stroke. Our study found a dose-response association between higher Dkk-1 at baseline and the primary outcome within 1 year after acute ischemic stroke. This association was independent of established risk factors for stroke prognosis, and subgroup analyses further confirmed these findings. Furthermore, adding serum Dkk-1 to conventional risk factors could improve risk prediction for primary outcome. However, we did not find a significant association of serum Dkk-1 with stroke recurrence or vascular events within 1 year after ischemic stroke. These findings indicated that serum Dkk-1 might be a potential biomarker in the prediction of clinical outcomes among patients with acute ischemic stroke, but it still needed to be further replicated by other studies from various populations. As the best-characterized antagonist of Wnt canonical pathway, 1 Dkk-1 seems to play important roles in the occurrence and development of cardiovascular disease. Dkk-1 expression has been reported to be increased in murine atherosclerotic lesions and human carotid plaques, 2 and serum Dkk-1 is identified as a novel biomarker for the presence of coronary atherosclerotic plaque. 18 Recently, several studies have discovered that serum Dkk-1 levels are increased in various atherosclerosis-related diseases, such as carotid atherosclerosis, 2 stable angina, 2 and myocardial infarction. 4, 5 Dkk-1 was also considered as an independent predictor for long-term poor prognosis among patients with acute coronary syndrome 6 and symptomatic aortic stenosis. 7 In terms of ischemic stroke, Dkk-1 was shown to be implicated in its pathophysiology processes. In an analysis based on 124 patients with acute ischemic stroke (62 large artery atherosclerotic stroke and 62 small artery occlusion stroke) and 62 healthy controls, patients with ischemic stroke were found to have increased serum Dkk-1 levels, and there was no difference of serum Dkk-1 levels between stroke subtypes. 3 Similarly, compared with healthy controls, another study reported that circulating Dkk-1 levels were higher both in 57 patients with acute ischemic stroke and 29 clinically stable patients with cerebrovascular disease. 10 However, after following up all patients with ischemic stroke at 3 months, both aforementioned studies found no association between serum Dkk-1 and clinical outcomes. 3, 10 It is noteworthy that both studies are underpowered because of small sample sizes and short follow-up time, so that the evidence for prognostic value of Dkk-1 on ischemic stroke is limited. To provide a more valid appraisal of the association between serum Dkk-1 and ischemic stroke, we conducted a prospective cohort study among 3178 patients with ischemic stroke and assessed their clinical outcomes at 1 year after stroke onset.
This study was based on the CATIS randomized clinical trial, including a large sample size and relatively long-term follow-up, which enabled us to perform analysis with high statistical power. Moreover, standardized protocols and strict quality control procedures were used in baseline data collection and outcome assessment during follow-up. Furthermore, comprehensive information about potential confounders was collected and controlled in the multivariate models. Therefore, the method in this study was appropriate and rigorous, and our study will provide more credible evidence for the role of serum Dkk-1 on clinical outcomes among patients with ischemic stroke. In the present study, we found that elevated serum Dkk-1 levels were associated with increased risk of primary outcome at 1 year after ischemic stroke onset. Given that Dkk-1 was reported to be able to promote enhanced release of inflammatory cytokines, 2 we adjusted high-sensitivity C-reactive protein and white blood cell counts in the multivariable models and performed further subgroup analyses stratified by high-sensitivity C-reactive protein and white blood cell counts to eliminate the confounding effects of the 2 inflammatory markers. We found that the significant association of serum Dkk-1 levels with primary outcome was independent of the 2 inflammatory markers, and there were no modified effects of the 2 inflammatory markers on the association between serum Dkk-1 levels and primary outcome, suggesting that serum Dkk-1 has additional prognostic value when inflammatory markers are considered. Conventional model included age, sex, time from onset to hospitalization, current smoking, alcohol consumption, dyslipidemia, blood glucose, systolic BP, log-transformed platelet counts, creatinine, high-sensitivity C-reactive protein, white blood cell counts, and NIHSS score at baseline, history of hypertension, history of coronary heart disease, history of diabetes mellitus, family history of stroke, ischemic stroke subtypes, and receiving immediate BP reduction. BP indicates blood pressure; Dkk-1, dickkopf-1; IDI, integrated discrimination improvement; NIHSS, National Institutes of Health stroke scale; and NRI, net reclassification improvement.
Platelet is an important cellular source of Dkk-1, and release of Dkk-1 from platelet occurs during activation of platelets, including clotting during collection of serum samples. 2 Indeed, in the present study, we found that serum levels of Dkk-1 significantly correlated with platelet counts ( Figure I online-only Data Supplement). Therefore, caution is needed when interpreting serum Dkk-1 values, and it may be argued that the high serum Dkk-1 levels in patients with ischemic stroke with poor prognosis is an ex vivo phenomenon reflecting enhanced release of Dkk-1 during coagulation. However, serum levels may reflect the capacity of platelets to release various molecules on massive activation, and this may be relevant to the in vivo situation within the infarction, where platelets are exposed to several potent activators. 19 This view is also confirmed by the study by Ueland et al. 2 They found that Dkk-1 levels were significantly higher in serum than in plasma among patients with angina although there was no difference between serum and plasma levels of Dkk-1 in healthy controls, suggesting increased release of Dkk-1 during platelet aggregation in patients with cardiovascular disease. Interestingly, serum Dkk-1 levels increased markedly in patients with angina, but there was no difference in platelet-poor plasma Dkk-1 levels between patients with angina and healthy controls, indicating that serum Dkk-1 may be more suitable as a biomarker for cardiovascular disease than plasma Dkk-1. In addition, we also adjusted platelet counts in the multivariable models and performed subgroup analysis stratified by platelet counts to weaken or even eliminate the confounding effects of platelet counts on the relationship between serum Dkk-1 and prognosis of ischemic stroke. We found that the association between them remained significant after adjustments of platelet counts and other conventional prognostic factors. Moreover, the significantly positive associations between high serum Dkk-1 and primary outcome were observed in both low-and high-platelet-count subgroups, and no significant interaction between serum Dkk-1 levels and platelet counts on primary outcome was observed.
Because of the high incidence of major disability and mortality after stroke 20 and underpowered prognostic ability of established traditional risk factors, 11, 12 it is urgent for us to identify novel and effective biomarker for ischemic stroke prognosis. Serum Dkk-1 could significantly improve the predictive power for primary outcome beyond established traditional risk factors (NRI, 10.11%; IDI, 0.21%), indicating that serum Dkk-1 at baseline may be a potential biomarker in the prediction of all-cause mortality or major disability among patients with ischemic stroke. Therefore, we hypothesized that serum Dkk-1 might be useful in risk stratification of all-cause mortality or major disability among patients with ischemic stroke and could assist the selection of high-risk patients in future clinical practice. If patients have high serum Dkk-1 levels at admission, they may be at high risk of all-cause mortality or major disability and should receive aggressive monitoring and therapeutic interventions. In addition, previous evidence showed that reducing or blocking Dkk-1 could protect neurons against focal ischemia 8 and decreased infarction volume, 9 suggesting that Dkk-1 may be a potential therapeutic target for ischemic stroke. It is of clinical interest to see whether Dkk-1 reduction with specific antagonists in the acute phase would improve prognosis of ischemic stroke.
The mechanisms underlying the detrimental effect of elevated Dkk-1 on the stroke prognosis are not well defined, but several potential pathophysiological pathways have been suggested. Wnt canonical pathway is involved in the regulation of survival, proliferation, and migration of vascular cells. 21 Therefore, as a potent antagonist of Wnt canonical pathway, Dkk-1 has been shown to promote the endothelial cell injury and induce endothelial dysfunction through inhibiting this pathway. 2, 22 Moreover, Dkk-1 is a mediator in platelet-mediated inflammatory response, and elevated expression of Dkk-1 can also drive inflammatory loop within the atherosclerotic lesion, leading to atherosclerotic plaque destabilization or even rupture. 2, 6 In addition, Dkk-1 was reported to be able to damage the integrity of blood-brain barrier and increase its leakage. 23 Furthermore, experimental animal studies demonstrated that Dkk-1 could contribute to the development of neuronal death after brain focal ischemia, 8, 9 thus increasing the risk of poor prognosis.
Our study has several limitations. First, this is an observational study based on the patients from CATIS, and a selection bias may exist. However, baseline characteristics of the participants in this study were similar to those from the China National Stroke Registry, 24 indicating that the selection bias may be minimal. Second, although several important potential confounders have been controlled in the multivariable models, there is also a possibility of residual confounding in our study. Third, serum Dkk-1 was tested only once at baseline, so we were unable to explore the association between Dkk-1 changes and clinical outcomes of ischemic stroke, although serum Dkk-1 levels were reported to remain stable within several days after ischemic stroke onset. 3 Fourth, the relatively few number of stroke recurrence and vascular events were observed during 1-year follow-up because the median severity of CATIS participants was relatively low (NIHSS score, 4 [2] [3] [4] [5] [6] [7] ), 13 which might limit our power to detect significant association between serum Dkk-1 and these outcomes. Finally, we did not collect the data of concurrent inflammatory diseases, such as pneumonia; so we could not examine the prognostic value of Dkk-1 in patients with concurrent inflammatory diseases. However, we found that the significant association between serum Dkk-1 and primary outcome of ischemic stroke persisted in the subgroups with high inflammatory markers, suggesting that the additional prognostic value of Dkk-1 remains in patients with ischemic stroke with concurrent inflammatory diseases. Further studies are needed to investigate this hypothesis.
Conclusions
In summary, we found that elevated Dkk-1 levels at baseline were associated with poor prognosis at 1 year after ischemic stroke onset, indicating that Dkk-1 may be a potential prognostic biomarker for ischemic stroke. Further prospective studies from other samples of patients with ischemic stroke are needed to validate our findings and to clarify the potential biological mechanisms.
